drugset / Trial / NCT05105867
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
Phase 0
Unknown
15 enrolled
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Gracell Biotechnologies (Shanghai) Co., Ltd. · collabKunming Hope of Health Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
It is a single-arm, open-label clinical study to assess the safety and efficacy of the Anti-CD19 Universal CAR-T Cells injection for patients with CD19+ refractory/relapsed B cell acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma.
Timeline
- Start
- 2021-09-29
- Primary completion
- 2024-08-31
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD19 Universal CAR-T Cells | Cell therapy | — | Intravenous |